@FierceMedDev: Italy's DiaSorin Group signed a Dx expansion deal with Trivitron for the Indian market. Asian expansion continues. Release | Follow @FierceMedDev
@MarkHFierce: 23andMe will seek FDA 510(k) clearance for its new personalized DNA test, the company disclosed. Release | Follow @MarkHFierce
@DamianFierce: Looking to boost its flagging CRM business, Boston Sci snagged CE marks for two MRI-friendly pacemakers. More | Follow @DamianFierce
> Roche Diagnostics ($RHHBY) is handing over its Cellavista technology, used to measure cellular expansion, to SynenTec, the German firm that invented it. More
> Teleflex Medical ($TFX) reported a .6% increase in net revenues for the second quarter, driven largely by double-digit growth from the orthopedics unit the company sold off this month. News
> GenMark Diagnostics ($GNMK) has finalized its deal with Advanced Liquid Logic to create an all-digital, in vitro diagnostic platform, combining the two companies' proprietary technologies. Item
> CardioDx is reporting encouraging results from a gene expression test designed to assess obstructive coronary artery disease. Release
> TCB Medical is among medical device startups that have turned to crowdfunding rather than venture capital. Release
Biotech News
@FierceBiotech: CIRM favors teamwork with $150M in new stem cell grants. Story | Follow @FierceBiotech
@JohnCFierce: Deja vu: Dimebon (remember it?) promising in mouse study for Alzheimer's. Scientists want to go back, try again. Release | Follow @JohnCFierce
@RyanMFierce: Biotech VC deals abound this week: Ultragenyx nailed down $15M, and now Mersana says it's found $27M more with help from deep pockets at NEA. | Follow @RyanMFierce
> Rare disease biotech nails down $15.1M in VC. Report
> Vertex surges as rival hep C contender plays catch-up in clinic. Story
> Dendreon shares plunge as new CEO brings out the ax (again). More
Pharma News
@FiercePharma: WSJ's list of 25 Best CFOs includes 3 drug company execs: Biogen, Allergan, Perrigo. List | Follow @FiercePharma
> Pfizer nears animal health IPO as cost-cutting boosts profits. Story
> Glaxo changes the guard at newly bought HGS. News
> Dendreon to slash 600 more jobs as Provenge sales lag. Article
> FDA nixes new gout use for Regeneron's Arcalyst. Item
Pharma Manufacturing News
@EricPFierce: It is out with the old and with the new at HGS now that GSK is in charge. More | Follow @EricPFierce
> Plant's IT mess nearly kills AZ growth in new markets. News
> Drug pricing figures into McKesson settlement, earnings. Article
Biotech Research News
> Another shot at treating Alzheimer's with Dimebon? Article
> 17 universities win NIH cash for tissue chip/drug safety testing. News
> CIRM favors teamwork with $150M in new stem cell grants. More
And Finally... The New York Times profiles former FDA employee Robert Smith, whose charges alleging the agency cut corners in its approval of medical devices led to the it apparently launching a surveillance operating against him and four other colleagues. Story (sub. req.)